CA2701608A1 - Novel compositions and methods for stimulating erythropoiesis in a mammal - Google Patents

Novel compositions and methods for stimulating erythropoiesis in a mammal Download PDF

Info

Publication number
CA2701608A1
CA2701608A1 CA2701608A CA2701608A CA2701608A1 CA 2701608 A1 CA2701608 A1 CA 2701608A1 CA 2701608 A CA2701608 A CA 2701608A CA 2701608 A CA2701608 A CA 2701608A CA 2701608 A1 CA2701608 A1 CA 2701608A1
Authority
CA
Canada
Prior art keywords
antibody
hvem
mammal
agonist
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2701608A
Other languages
English (en)
French (fr)
Inventor
Koji Tamada
Lieping Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
University of Maryland Baltimore
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2701608A1 publication Critical patent/CA2701608A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2701608A 2007-10-05 2008-10-03 Novel compositions and methods for stimulating erythropoiesis in a mammal Abandoned CA2701608A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99781807P 2007-10-05 2007-10-05
US60/997,818 2007-10-05
PCT/US2008/078769 WO2009046313A2 (en) 2007-10-05 2008-10-03 Novel compositions and methods for stimulating erythropoiesis in a mammal

Publications (1)

Publication Number Publication Date
CA2701608A1 true CA2701608A1 (en) 2009-04-09

Family

ID=40526962

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2701608A Abandoned CA2701608A1 (en) 2007-10-05 2008-10-03 Novel compositions and methods for stimulating erythropoiesis in a mammal

Country Status (5)

Country Link
US (1) US20100203047A1 (https=)
EP (1) EP2195344A4 (https=)
JP (1) JP2010540660A (https=)
CA (1) CA2701608A1 (https=)
WO (1) WO2009046313A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011163506A2 (en) * 2010-06-23 2011-12-29 University Of Louisville Research Foundation, Inc. Methods and kits for predicting a response to an erythropoietic agent
AU2016334051B2 (en) * 2015-10-06 2023-10-26 Alector Llc Anti-TREM2 antibodies and methods of use thereof
BR112019022752A2 (pt) 2017-08-03 2020-05-19 Alector Llc anticorpos anti-trem2 e métodos de uso dos mesmos

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5830851A (en) * 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
WO1998051346A1 (en) * 1997-05-12 1998-11-19 Smithkline Beecham Corporation Human tumor necrosis factor receptor-like 2 (tr2) antibodies
WO2000061637A1 (en) * 1999-04-14 2000-10-19 Smithkline Beecham Corporation Erythropoietin receptor antibodies
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
EP1336619A3 (en) * 2002-02-19 2003-12-10 Millenium Pharmaceuticals, Inc. Combination of a HVEM-LIGHT inhibitor and an immunosuppressive agent in the treatment or prevention of immune disorders
CA2482938A1 (en) * 2002-04-12 2003-10-23 Human Genome Sciences, Inc. Antibodies that specifically bind to tr2
AU2003300184B8 (en) * 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
CA2586615C (en) * 2004-11-12 2017-06-27 Genentech, Inc. Pro87299 (btla), and variants thereof, for treating immune related disorders
US8188232B1 (en) * 2004-11-15 2012-05-29 Washington University In St. Louis Compositions and methods for modulating lymphocyte activity
CA2649384A1 (en) * 2006-04-14 2007-10-25 Amgen Inc. Erythropoietin receptor agonists
WO2008146101A1 (en) * 2007-06-01 2008-12-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Ligands of hvem for treating hematologic malignancies and autoimmune diseases

Also Published As

Publication number Publication date
EP2195344A2 (en) 2010-06-16
US20100203047A1 (en) 2010-08-12
WO2009046313A3 (en) 2009-05-22
WO2009046313A2 (en) 2009-04-09
JP2010540660A (ja) 2010-12-24
EP2195344A4 (en) 2011-07-06

Similar Documents

Publication Publication Date Title
JP7610302B2 (ja) Ｃｃｒ８抗体及びその用途
JP2024088696A (ja) ヒトネクチン４に特異的な抗体
US20210220472A1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
JP3225493B2 (ja) エリトロポエチン受容体を活性化する抗体
CA2318405C (en) Antibodies to death receptor 4(dr4) and uses thereof
CN114341189A (zh) 全新il-15前药及其应用
JP2022514693A (ja) Ｍｕｃ１８に特異的な抗体
EA023665B1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
KR20050057631A (ko) 2특이적 항-ｅｒｂ-ｂ 항체 및 종양 치료법에서의 이들의용도
JP2022523710A (ja) Ｃｄ４４に特異的な抗体
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
KR20220119117A (ko) 종양 특이적 claudin 18.2 항체
JP2023520587A (ja) 癌及び感染症の治療のためのＮＫｐ４６に対する抗体及びそのコンストラクト
US20100203047A1 (en) Novel Compositions And Methods For Stimulating Erythropoiesis In A Mammal
CN119403833A (zh) 分离的抗原结合蛋白及其用途
WO2023138638A1 (zh) 抗tigit和pd-l1的双特异性抗原结合蛋白及其用途
JP2024507124A (ja) Ｃｄ１１２ｒに対する抗体およびその使用
KR20250109195A (ko) 에리트로포이에틴 수용체의 합성 항체 작용제
EP4650368A1 (en) Tetravalent agonists of erythropoietin receptor
CN120230216B (zh) 抗lair1抗体及其用途
EP4293047A1 (en) Anti-pd-l1 antibody and use thereof
CN121108347B (zh) 抗ly6g6d抗体或其抗原结合片段及其用途
CN118271438B (zh) 抗cgrp抗体或其抗原结合片段及其用途
CN118546252A (zh) 抗trem2抗体及其用途
WO2024153163A1 (zh) 抗cd93抗体及其应用

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20141003